Invasive Lobular Carcinoma Of The Breast: Experience For Centre Mohammed VI For The Treatment Of Cancers
Ibrahim Khalil AHMADAYE, Ben M'Sik Faculty of Sciences, University Hassan II Casablanca, Morocco
BENDAHHOU K. 2
, SAILE R. 3
, AFGHAR S. 2
, MESTAGHANMI H. 1
, BENIDER A. 4
1 Laboratory Pathophysiology and Molecular Genetics. Ben M'Sik Faculty of Sciences, University Hassan II Casablanca
2 Cancer Registry of Greater Casablanca
3 Laboratory of Biology and Health. Research Unit Associated to CNRST - URAC 34. Ben M'Sik Faculty of Science, University Hassan II Casablanca
4 Mohammed VI Centre for the treatment of cancers, CHU Ibn Rochd Casablanca
This is a retrospective study conducted over two years (January 2014-December 2015), including all cases of invasive lobular carcinoma of the breast supported at the centre Mohammed VI.
The purpose of our study was to describe the epidemiological, clinical, biological and therapeutic of this cancer.
62 cases of invasive lobular carcinoma were recorded by central cancer registry, whose average age is 52.6 ± 11.8 years, ranging from 27 to 84 ans. 51.6% of patients were married, 19.4% used oral contraceptives and 27.4% were postmenopausal at diagnosis. The notion of family history of breast cancer was observed in 3.2% of cases. The left and right tumour laterality was respectively 48.4% and 46.8% of cases, 4.8% cases were bilateral.
The clinical TNM stage was T1 and T2 (35.5%), N0 (48.4%) N1 (30.0%) and metastasis was observed in 3.2% of cases. The SBR histologic grade II was the most common in 58.1% of cases. The most common stage at diagnosis was stage III (38.7%). Hormone receptor positivity was estrogens in 56.5% of cases, to progesterone in 54.8% of cases and the Her2 receptor over expression was observed in 10.0% of cases. The molecular phenotype of the tumours was more majority luminal A (50.0%), while the luminal B and Her2 that were respectively 4.8% and 1.6% of cases. Negative triple represented 8.1% of cases.
69.4% of patients received surgical treatment as adjuvant chemotherapy; radiotherapy and hormone therapy was administered to 51.6%, respectively, 35.5% and 16.1% of cases. 1.6% of cases had a recurrence.
The invasive lobular breast carcinoma is relatively rare in our centre. It is often diagnosed at an advanced stage and is conventionally recognized by its unfavourable prognosis. Therapeutic management varies depending on the condition of the patients, but surgery remains the primary treatment.